HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Bretylium, an organic quaternary amine, inhibits the Na,K-ATPase by binding to the extracellular K-site.

Abstract
The quaternary amine, bretylium, is a class III antiarrhythmic drug used to treat ventricular tachycardia and fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. While the Na,K-ATPase has been the pharmacological target of cardiac glycosides for over a century, recent evidence has shown that bretylium may also inhibit the Na pump. Our experimental findings support and extend these previous reports and provide definitive evidence supporting the previous suggestion that bretylium and K compete for the Na pump. We find that bretylium inhibits the Na pump in a dose-dependent manner in both Na,K-ATPase (IC(50) 4.5 mM) and Rb flux experiments (IC(50) 3.5 mM). Furthermore, we show that bretylium and Rb(+) competes for an extracellular site by measuring ouabain-sensitive (86)Rb flux in intact human red blood cells; that is, there is an apparent increase in K(m) for Rb(+) in the presence of 5 mM bretylium, while V(max) remains unchanged. We also determined that unlike K(+), bretylium does not facilitate the hydrolysis of E2-P. However, it stabilizes this conformation by reducing the ability of K(+) to facilitate dephosphorylation. Finally, we show that bretylium, like K(+), reduces [(3)H]ouabain binding to the Na pump. Taken together, these data are consistent with bretylium binding to the extracellular facing cation site within the E2-P state of the enzyme. Moreover, these findings suggest that bretylium may serve as an effective tool for freezing the pump in an extracellularly cation-bound phosphorylated intermediate, which will aid in future structural analyses.
AuthorsJeff B Helms, Krista L Arnett, Craig Gatto, Mark A Milanick
JournalBlood cells, molecules & diseases (Blood Cells Mol Dis) 2004 May-Jun Vol. 32 Issue 3 Pg. 394-400 ISSN: 1079-9796 [Print] United States
PMID15121098 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Anti-Arrhythmia Agents
  • Bretylium Compounds
  • Quaternary Ammonium Compounds
  • Sodium-Potassium-Exchanging ATPase
  • Rubidium
  • Potassium
  • bretylium
Topics
  • Anti-Arrhythmia Agents (pharmacology)
  • Binding Sites
  • Binding, Competitive
  • Bretylium Compounds (pharmacology)
  • Dose-Response Relationship, Drug
  • Erythrocytes (metabolism)
  • Humans
  • Kinetics
  • Phosphorylation
  • Potassium (metabolism)
  • Protein Conformation
  • Quaternary Ammonium Compounds (pharmacology)
  • Rubidium (metabolism)
  • Sodium-Potassium-Exchanging ATPase (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: